Guillaume Gravel1, Sophie Leboulleux2, Lambros Tselikas3, Flora Fassio2, Mohamed Berraf3, Amandine Berdelou2, Bakar Ba3, Segolene Hescot2, Julien Hadoux2, Martin Schlumberger2, Abir Al Ghuzlan4, France Nguyen5, Mathieu Faron6, Thierry de Baere3, Eric Baudin2, Frederic Deschamps3. 1. Department of Interventional Radiology, Gustave Roussy Cancer Center, 114 rue Edouard Vaillant, 94805, Villejuif, France. guillaume.gravel@gustaveroussy.fr. 2. Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy Cancer Center, 114 rue Edouard Vaillant, 94805, Villejuif, France. 3. Department of Interventional Radiology, Gustave Roussy Cancer Center, 114 rue Edouard Vaillant, 94805, Villejuif, France. 4. Department of Anatomopathology, Gustave Roussy Cancer Center, 114 rue Edouard Vaillant, 94805, Villejuif, France. 5. Department of Radiotherapy, Gustave Roussy Cancer Center, 114 rue Edouard Vaillant, 94805, Villejuif, France. 6. Department of Surgery, Gustave Roussy Cancer Center, 114 rue Edouard Vaillant, 94805, Villejuif, France.
Abstract
PURPOSE: Bone metastases (BM) and skeletal-related events (SRE) are frequent in patients with malignant pheochromocytoma and paraganglioma (PPM) and the best modality of prevention unknown. The role of interventional radiology (IR) techniques for the prevention of SRE in the multidisciplinary management of malignant PPM has not been evaluated in that setting. METHODS: Single referral center retrospective review of all patients with malignant PPM with BM from 2000 to 2016. The primary endpoint was the time to first serious SRE (TTSRE). At time of inclusion, patients with high bone tumor burden disease were defined as those having more than five BM with the biggest exceeding 2 cm (Group A) and patients with moderate bone tumor burden disease were defined as those having five or less BM or no BM exceeding 2 cm (Group B). RESULTS: A total of 28 patients were included in this study. Thirteen were treated by IR techniques for prevention of first serious SRE. After a median follow-up of 48.2 months, the median TTSRE was not reached in patients treated by IR techniques and was 26.0 months in patients without IR procedures (p = .058). When comparing patients in group B, TTSRE was significantly higher in patients treated by IR (10 patients) when compared to patients without IR procedures (12 patients) (p = .021). CONCLUSIONS: IR techniques may help to delay the occurrence of first serious SRE in patients with malignant PPM with moderate bone tumor burden disease. Prospective studies are expected to confirm these results.
PURPOSE: Bone metastases (BM) and skeletal-related events (SRE) are frequent in patients with malignant pheochromocytoma and paraganglioma (PPM) and the best modality of prevention unknown. The role of interventional radiology (IR) techniques for the prevention of SRE in the multidisciplinary management of malignant PPM has not been evaluated in that setting. METHODS: Single referral center retrospective review of all patients with malignant PPM with BM from 2000 to 2016. The primary endpoint was the time to first serious SRE (TTSRE). At time of inclusion, patients with high bone tumor burden disease were defined as those having more than five BM with the biggest exceeding 2 cm (Group A) and patients with moderate bone tumor burden disease were defined as those having five or less BM or no BM exceeding 2 cm (Group B). RESULTS: A total of 28 patients were included in this study. Thirteen were treated by IR techniques for prevention of first serious SRE. After a median follow-up of 48.2 months, the median TTSRE was not reached in patients treated by IR techniques and was 26.0 months in patients without IR procedures (p = .058). When comparing patients in group B, TTSRE was significantly higher in patients treated by IR (10 patients) when compared to patients without IR procedures (12 patients) (p = .021). CONCLUSIONS: IR techniques may help to delay the occurrence of first serious SRE in patients with malignant PPM with moderate bone tumor burden disease. Prospective studies are expected to confirm these results.
Entities:
Keywords:
Bone metastases; Interventional radiology; Paraganglioma; Pheochromocytoma; Skeletal-related events
Authors: Mark O Baerlocher; Wael E Saad; Sean Dariushnia; John D Barr; J Kevin McGraw; Boris Nikolic Journal: J Vasc Interv Radiol Date: 2013-11-15 Impact factor: 3.464
Authors: David A Palma; Joseph K Salama; Simon S Lo; Suresh Senan; Tom Treasure; Ramaswamy Govindan; Ralph Weichselbaum Journal: Nat Rev Clin Oncol Date: 2014-06-24 Impact factor: 66.675
Authors: A Cotten; N Boutry; B Cortet; R Assaker; X Demondion; D Leblond; P Chastanet; B Duquesnoy; H Deramond Journal: Radiographics Date: 1998 Mar-Apr Impact factor: 5.333
Authors: Henri J L M Timmers; Clara C Chen; Jorge A Carrasquillo; Millie Whatley; Alexander Ling; Graeme Eisenhofer; Kathryn S King; Jyotsna U Rao; Robert A Wesley; Karen T Adams; Karel Pacak Journal: J Natl Cancer Inst Date: 2012-04-18 Impact factor: 13.506
Authors: Herbert Chen; Rebecca S Sippel; M Sue O'Dorisio; Aaron I Vinik; Ricardo V Lloyd; Karel Pacak Journal: Pancreas Date: 2010-08 Impact factor: 3.327
Authors: Graeme Eisenhofer; Stefan R Bornstein; Frederieke M Brouwers; Nai-Kong V Cheung; Patricia L Dahia; Ronald R de Krijger; Thomas J Giordano; Lloyd A Greene; David S Goldstein; Hendrik Lehnert; William M Manger; John M Maris; Hartmut P H Neumann; Karel Pacak; Barry L Shulkin; David I Smith; Arthur S Tischler; William F Young Journal: Endocr Relat Cancer Date: 2004-09 Impact factor: 5.678
Authors: Katherine Van Loon; Li Zhang; Jennifer Keiser; Cendy Carrasco; Katherine Glass; Maria-Teresa Ramirez; Sarah Bobiak; Eric K Nakakura; Alan P Venook; Manisha H Shah; Emily K Bergsland Journal: Endocr Connect Date: 2014-11-27 Impact factor: 3.335
Authors: Camilo Jimenez; Guofan Xu; Jeena Varghese; Paul H Graham; Matthew T Campbell; Yang Lu Journal: Curr Oncol Rep Date: 2022-01-21 Impact factor: 5.075
Authors: Jacob Kohlenberg; Brian Welch; Oksana Hamidi; Matthew Callstrom; Jonathan Morris; Juraj Sprung; Irina Bancos; William Young Journal: Cancers (Basel) Date: 2019-02-07 Impact factor: 6.639